Categories Consumer, Earnings

Altria shares edge down after Q1 earnings miss

Shares of Altria Group Inc. (NYSE: MO) fell 2.5% during pre-market trading on Thursday after the tobacco company reported an earnings miss.  Adjusted EPS fell 5.3% to $0.90, hurt by higher interest expense as a result of its recently issued debt. This missed the street projection by 2 cents.

On a reported basis, net income dropped 40% $0.60 per share.

 

Altria Q1 2019 earnings IG

Net revenues fell 6% to $4.39 billion, missing analysts’ projection of $4.55 billion.

Net revenues in Smokeable products decreased 8.8%, while that from Smokeless products increased 2.9% during the quarter. Marlboro retail share declined 0.2 share points to 43.1% year-over-year.

READ: THE QUESTION EVERY POT INVESTOR ASKS HIMSELF – AURORA CANNABIS OR HEXO?

In the Wine segment, net revenues rose 6.3%, as wine shipment volume jumped 8% to approximately 1.9 million cases.

Outlook

For full-year 2019, Altria reaffirmed its projection of adjusted EPS growth of 4-7% to a range of $4.15 to $4.27. Meanwhile, the company revised its expectation for total domestic cigarette industry volume. It now expects the volume to decline 4-5% as it believes increased gas prices have impacted adult tobacco consumer behavior.

CEO Howard Willard said, “After taking steps to position Altria for long-term success at the end of 2018, we entered 2019 with an evolved business platform that includes our strong core tobacco businesses and new strategic investments with tremendous potential for growth.”

Last quarter, Altria had acquired stakes in cannabinoid company Cronos Group (CRON) and vaping company JUUL (JUUL). The company took a 45% stake in Cronos for around $1.8 billion and a 35% stake in JUUL for $12.8 billion.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top